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Summary
Background The Dermatology Life Quality Index (DLQI) rates ‘not relevant’
responses (NRRs) as the item on the questionnaire having no impact on the
patients’ lives at all. The DLQI-Relevant (DLQI-R) is a recently developed scoring
that adjusts the total score of the questionnaire for the number of NRRs indicated
by a patient.
Objectives To compare the discriminatory power of the original and DLQI-R scor-
ing approaches in terms of absolute and relative informativity.
Methods Cross-sectional data from 637 patients with morphea, pemphigus and
psoriasis were used for the analyses. To assess absolute and relative informativity,
Shannon’s index and Shannon’s evenness index were calculated for the 10 items
on the questionnaire and for DLQI and DLQI-R total scores.
Results Mean DLQI and DLQI-R scores of patients were 613 vs. 691. In the sub-
set of patients with NRRs (n = 261, 41%), absolute informativity was higher
with the DLQI-R scoring for all eight items with NRR options in all three condi-
tions. The DLQI-R exhibited a better relative informativity in 8, 8 and 6 items in
pemphigus, morphea and psoriasis, respectively. The DLQI-R led to an improve-
ment in average item-level informativity in all DLQI score bands up to 20 points.
Regarding total scores, the DLQI-R produced both a higher absolute and relative
informativity in all three conditions.
Conclusions In patients with morphea, pemphigus and psoriasis, DLQI-R scoring
improves the discriminatory power of the questionnaire by benefiting from the
additional information in NRRs. DLQI-R scoring may be useful both in clinical
practice and research. A scoring chart has been developed to aid physicians with
scoring.
What’s already known about this topic?
• The original scoring of the Dermatology Life Quality Index (DLQI) rates ‘not rele-
vant’ responses as the item of the questionnaire having no impact on the patients’
lives at all.
• DLQI-Relevant (DLQI-R) is a new scoring developed in 2018 that adjusts the total
score of the questionnaire for the number of ‘not relevant’ responses indicated by
patients.
• The discriminatory power of the DLQI-R compared with the DLQI has not yet been
investigated.
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What does this study add?
• In patients with psoriasis, pemphigus and morphea, DLQI-R scoring improves the
discriminatory power of the questionnaire by benefiting from the additional infor-
mation in ‘not relevant’ responses.
What are the clinical implications of this work?
• DLQI-R scoring may help to more accurately quantify patients’ health-related qual-
ity of life both in clinical practice and research.
• A scoring chart has been developed to aid physicians with scoring.
The Dermatology Life Quality Index (DLQI) is the most
commonly applied questionnaire to measure health-related
quality of life (HRQoL) in dermatology.1 Since its develop-
ment in the early 1990s, it has been used in over 40 differ-
ent skin conditions worldwide.2,3 It is recognized as being
useful in various health service settings including primary
care, day-case treatment, outpatient consultations, inpatient
care and teledermatology.4,5 Moreover, the DLQI is the most
frequently used HRQoL measure in dermatological clinical
trials.6,7
In eight out of the 10 items of the DLQI, patients may
answer that the item does not apply to their life [‘not rele-
vant’ response (NRR)]. The original scoring of the DLQI sug-
gests rating NRRs as the item having no impact on the
patient’s HRQoL at all. In 2018–2019, three large independent
studies from the U.S.A. and Europe raised concerns about
scoring NRRs on the DLQI.8–10 To address the issue, a new
scoring, the DLQI-Relevant (DLQI-R) has been developed that
adjusts the total DLQI score of patients for the number of
NRRs.11 The DLQI-R showed good validity and responsiveness
to change in patients with psoriasis.11–14 However, a U.S.
study did not recommend the use of the DLQI-R and called
for additional refinement and validation.12 In addition to
validity and responsiveness, other important measurement
properties of the DLQI-R scoring, such as discriminatory
power, need to be confirmed to encourage its use in clinical
practice and research.
Discriminatory power is often measured by the form of
informativity indicating whether an instrument can define the
full range of potential health states, and whether it is sensitive
over this range.15,16 As the original scoring of DLQI does not
differentiate between responses that are marked ‘not at all’
and ‘not relevant’, valuable information may be discarded
about patients when using the original DLQI scoring instead
of DLQI-R that may result in a decrease in the discriminatory
power of the questionnaire. This study therefore aims to com-
pare the informativity of the DLQI and DLQI-R scoring meth-
ods with regard to the 10 items of the questionnaire as well
as the total scores in three conditions (morphea, pemphigus
and psoriasis).
Patients and methods
Patient populations
A large dataset containing DLQI data from four earlier cross-
sectional surveys in three diagnoses (morphea, pemphigus and
psoriasis) were used for the analyses.17–24 All these surveys
were carried out between 2012 and 2017 at four university
dermatology clinics in Hungary. Only patients with no miss-
ing DLQI total scores were eligible to be included in this com-
parative analysis.
Dermatology Life Quality Index scoring methods
Both DLQI and DLQI-R total scores were calculated for each
patient. According to the DLQI scoring, four distinct scores can
be attached to all items of the questionnaire regardless of the
number of response options in that item: ‘not at all’ or ‘not rele-
vant’, 0; ‘a little’, 1; ‘a lot’, 2; and ‘very much’, 3 (Table 1).1
This scoring method makes no difference between ‘not at all’
and ‘not relevant’ responses. The DLQI total score is calculated
by summing the score of the 10 items. The total score is
expressed on a scale ranging between 0 and 30, where a higher
score represents a greater impairment in HRQoL.
The DLQI-R scoring formula distinguishes between the ‘not
at all’ and ‘not relevant’ responses for items 3 to 10 of the
questionnaire.11 For each patient, the DLQI-R score is esti-
mated as a product of the original DLQI score and the rate of
the total number of items to the relevant items of the ques-
tionnaire. Compared with the 31 possible distinct scores with
the original scoring, the DLQI-R scoring may result in 97
unique scores that may take on not only integers but decimal
numbers.
Assessing discriminatory power
Shannon’s indices
Reliability, validity and responsiveness are three key qualities
for HRQoL measures.25 An underlying property of these three
concepts is the discriminatory power that indicates the capacity
© 2019 The Authors. British Journal of Dermatology
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of the instrument to distinguish between different levels of
HRQoL.16 A good discriminatory power is essential to differen-
tiate between groups of patients, for example, when distin-
guishing between mild and moderate-to-severe disease,
determining whom to treat or judging therapeutic response.
Discriminatory power of health classification systems can be
expressed in terms of absolute and relative informativity.
HRQoL instruments function best when they are not only able
to capture the maximum amount of information about the
patients (absolute informativity), but also their response
options are evenly used by the patients (relative informativity).
In this article, we follow a methodology to assess informativity
using Shannon’s indices proposed by Janssen et al.16,26 Firstly,
Shannon’s indices were applied to assess the item-level informativ-
ity of the DLQI and DLQI-R. Secondly, the Shannon’s indices were
calculated for the DLQI and DLQI-R total scores. Since the DLQI-R
scoring only alters the total score of patients who indicated at least
one NRR, the ‘true’ difference between the two scoring methods
can be detected in this group of patients and is expected to be
smaller in the total sample. Thus, all calculations were first carried
out for the subset of patients with NRRs and then for the total
sample involving patients with and without NRRs.
To assess absolute informativity of the two different DLQI
scorings, the Shannon’s index (H0) was computed as follows:
H0 ¼ 
XC
i¼1
pi log2 pi;
where C denotes the number of possible categories (e.g.
responses) in an item of the DLQI, and pi ¼ niN the proportion
of observations in the ith category (i = 1, . . ., C) where ni is
the observed number of responses in category i and N is the
total sample size. The higher the H0 index, the more informa-
tion is captured by the item. The H0 is a function of the num-
ber of categories and their evenness.16
To measure relative informativity [i.e. to test how a system
performs compared with its potential maximum (H0max)] a
Shannon’s evenness index (J0) was calculated: J0 ¼ H0H0max, where
H0max ¼ log2C.
In contrast to H0, the J0 is independent from the number of
categories. J0 values range between 0 and 1, where 1 refers to
a perfectly even distribution.16
Shannon’s indices for Dermatology Life Quality Index
items
To calculate Shannon’s indices for DLQI items, C represents
the number of response options per each item. For the origi-
nal DLQI scoring, as both ‘not relevant’ and ‘not at all’
responses are scored as ‘0’, C = 4 for all items. In contrast,
using the DLQI-R score, C = 4 for items 1 and 2 that have no
NRR options, but C = 5 for all other items that distinguish
between ‘not at all’ and ‘not relevant’ responses. H0max values
are equal to log24 = 2 for all DLQI items and for the first two
items of DLQI-R. For items 3–10 on the DLQI-R H0max can be
computed as log25 = 232. Suppose, for example, that item 6
(sport) is scored by 10 patients as follows: NRR (n = 3), not
at all (n = 1), a little (n = 2), a lot (n = 3) and very much (n
= 1). Shannon’s index (H0) and Shannon’s evenness index (J0)
for the item sport in DLQI would be calculated as follows:
Table 1 Characteristics of the Dermatology Life Quality Index (DLQI) and DLQI-Relevant (DLQI-R) scoring methods
DLQIa (Finlay
and Khan 1994)1
DLQI-Ra
(Rencz et al. 2018)11
Classification system
Number of response options considered for scoring
Item 1 (sore, itchy, painful) 4 4
Item 2 (embarrassment) 4 4
Item 3 (shopping /home) 4 5
Item 4 (clothes) 4 5
Item 5 (social activities) 4 5
Item 6 (sport) 4 5
Item 7 (working/studying) 4 5
Item 8 (interpersonal problems) 4 5
Item 9 (sexual difficulties) 4 5
Item 10 (treatment difficulties) 4 5
Total number of health states defined 1 048 576 6 250 000
Scoring
Scoring formula DLQI ¼P10
i¼1
dlqii DLQI-R ¼ DLQI 1010NRR
Score range 0–30 0–30
Number of possible scores 31 97
Arithmetic characteristics of the scores integers integers or decimals
dlqii, the score on the ith item of the questionnaire; NRR, number of ‘not relevant’ responses.
aBoth DLQI and DLQI-R scorings are based on
the same DLQI questionnaire, they merely differ in how the scores are estimated from responses.
© 2019 The Authors. British Journal of Dermatology
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H0DLQI6 ¼
3þ 1
10
log2
3þ 1
10
 
þ 2
10
log2
2
10
 
þ 3
10
log2
3
10
 
þ 1
10
log2
1
10
 !
¼ 1846 and J0DLQI6 ¼
H0DLQI6
H0max
¼ 1846
2
¼ 0923:
Likewise, for DLQI-R the Shannon’s indices may be calculated
as follows:
H0DLQIR6 ¼
3
10
log2
3
10
 
þ 1
10
log2
1
10
 
þ 2
10
log2
2
10
 
þ 3
10
log2
3
10
 
þ 1
10
log2
1
10
 !
¼ 2171 and J0DLQIR6 ¼
H0DLQIR6
H0max
¼ 2171
2322¼ 0935:
The differences in informativity between the DLQI-R and
DLQI were expressed as ratios of Shannon’s indices for each
item of the questionnaire in each condition. The DLQI-R was
considered superior in terms of informativity if it showed a
ratio of
H0DLQIR
H0DLQI
[ 1 along with
J0DLQIR
J0DLQI
 1.
Average Shannon’s indices for Dermatology Life Quality
Index items per score bands
To compare the informativity of the DLQI and DLQI-R in
patients with different severity levels, we classified DLQI scores
in the pooled dataset based on the banding system developed by
Hongbo et al.27 These bands describe the overall impact of skin
disease on HRQoL: 0,‘ no effect’; 2–5, ‘small effect’; 6–10,
‘moderate effect’; 11–20, ‘very large effect’; 21–30, ‘extremely
large effect’. The average H0 and J0 index values of the 10 items
of the DLQI and DLQI-R were compared for each score band.
Shannon’s indices for Dermatology Life Quality Index
(DLQI) and DLQI-Relevant total score
To estimate Shannon’s indices for the DLQI and DLQI-R total
scores, the numbers of categories (C) were equal to the possible
number of total scores in the questionnaire. As suggested by ear-
lier research,26 we rounded the DLQI-R scores to the nearest
integers so that the DLQI and DLQI-R have an identical number
of possible total scores (i.e. 31). Thus, H0max values were
log231 = 495 for both the DLQI and DLQI-R. All analyses were
performed by using Excel 2016 (Microsoft, Redmond, WA,
U.S.A.).
Results
Study populations
The dataset contained DLQI responses from 637 patients
[morphea (n = 101), pemphigus (n = 108) and psoriasis (n =
428)]. Age of respondents ranged from 18 to 93 years, with
means across studies ranging from 492 (psoriasis) to 571
(pemphigus) (Table 2). The lowest rate of women was
observed in psoriasis (350%) and the highest in morphea
(842%).
Distribution of responses on the 10 items of the DLQI are
presented in Table S1 (see Supporting Information). Mean
DLQI scores in the three patient populations varied from 399
(morphea) to 678 (psoriasis). The mean DLQI-R scores in
the population were slightly higher compared with the DLQI
varying from mean 454 (morphea) to 744 (psoriasis). Over-
all, 36 (84%), 4 (40%) and 20 (185%) of psoriasis, mor-
phea and pemphigus patients, respectively, moved to a
different descriptor band using the DLQI-R score. The propor-
tion of patients with NRRs was the lowest in morphea
(366%) and the highest in pemphigus (537%).
Item-level informativity
In the subset of patients with NRRs, absolute informativity
(H0) of the DLQI was the highest in psoriasis (range 061–
199), followed by pemphigus (range 029–187) and the
lowest for morphea (range 048–170). For all three condi-
tions, in items 3–10 (i.e. items with NRR options), the DLQI-
R exhibited higher H0 values: psoriasis (range 125–207),
pemphigus (065–206) and morphea (128–197), respec-
tively (Table S2; see Supporting Information). A very large
improvement in H0 was observed in items 6, 7, 9 and 10 for
morphea, and in items 6 and 9 for psoriasis and pemphigus
(Fig. 1).
Range of relative informativity (J0) indices per DLQI items
varied considerably across conditions: morphea (024–085),
pemphigus (015–094) and psoriasis (030–099). Corre-
sponding values for the DLQI-R were better: 055–085,
028–094 and 054–099. Considering the eight items of the
questionnaire with NRRs, by using the DLQI-R, J0 remained
improved for eight of eight items in morphea and pemphigus
and for six of eight items in psoriasis (items 3, 5, 6, 7, 8 and
9) (Fig. 1). In all three conditions, the greatest improvement
in H0 and J0 values was achieved in items 6 (sport) and 9
(sexual difficulties).
As expected, the improvement in absolute and relative
informativity achieved with the DLQI-R was lower in the
pooled dataset because of the identical DLQI and DLQI-R
scores in patients indicating no NRRs (Table S2; see Support-
ing Information).
Average item-level informativity by Dermatology Life
Quality Index score bands
In patients with NRRs (n = 261), H0 and J0 values showed a
gradual rise from 0 to 10 points, reached a peak in the 11–20
band, then declined in the band of 21–30 points (Fig. 2).
Compared with the DLQI, the DLQI-R led to an improvement
in H0 for all bands. J0 index values for DLQI-R were identical
or higher in all bands with the exception of the most severe
one (DLQI 21–30). A very similar trend was visible for the
© 2019 The Authors. British Journal of Dermatology
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Fig 1. Ratios of Shannon’s indices (H0DLQI-R to H0DLQI or J0DLQI-R to J0DLQI) per items on the questionnaire in patients with NRRs (n = 261, log2-
based scale). DLQI items: 1, sore, itchy, painful; 2, embarrassment; 3, shopping/home; 4, clothes; 5, social activities; 6, sport; 7, working/
studying; 8, interpersonal problem; 9, sexual difficulties; 10, treatment difficulties. Note that there are no differences between Shannon’s indices
(H0 and J0) on the DLQI and DLQI-R for items 1 and 2 on the questionnaire as these two items have no NRR option. The DLQI-R is considered
superior in terms of informativity if it demonstrates a H0 ratio of > 1 along with a J0 ratio of ≥ 1. DLQI, Dermatology Life Quality Index; DLQI-R,
DLQI-Relevant; N/A, not applicable; NRR, ‘not relevant’ response.
Table 2 Characteristics of the patient populations
Morphea Pemphigus Psoriasis Pooled dataset
All patients, n 101 108 428 637
Age, years: mean  SD 568  148 571  148 492  143 518  149
Women, % 842 639 35 57
Biological therapy, % N/A 0 437 294
DLQI, mean  SD 399  479 556  698 678  738 613  703
DLQI-R, mean  SD 454  577 703  840 744  798 691  781
Patients with NRRs, n (%) 37 (366) 58 (537) 166 (388) 261 (410)
1 NRR, % 139 139 196 177
2 NRRs, % 109 111 114 113
3 NRRs, % 4 102 51 58
4 NRRs, % 5 83 16 33
5 NRRs, % 1 37 02 09
6 NRRs, % 2 19 05 09
7 NRRs, % 0 09 0 02
8 NRRs, % 0 37 02 08
Age, years: mean  SD 614  145 605  156 557  143 576  148
Women, % 919 655 44 552
Biological therapy, % N/A 0 373 23
DLQI, mean  SD 462  555 564  586 723  629 651  615
DLQI-R, mean  SD 613  748 836  845 894  775 841  790
DLQI, Dermatology Life Quality Index; DLQI-R, DLQI-Relevant; N/A, not applicable; NRR, ‘not relevant’ response.
© 2019 The Authors. British Journal of Dermatology
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total sample including patients with and without NRRs (n = 637);
however, J0 indices started to fall from the band DLQI 11–20.
Informativity of Dermatology Life Quality Index (DLQI)
and DLQI-Relevant total scores
In the subset of patients with NRRs, the DLQI-R scoring led
to a higher absolute informativity and also a higher relative
informativity establishing a better distributional evenness
(Table 3). Considering all patients irrespective of NRRs, both
absolute and relative informativity were higher for the DLQI-R
in all three conditions.
Discussion
In this study, we compared the discriminatory power of the
DLQI and DLQI-R scorings in terms of informativity in
patients with morphea, pemphigus and psoriasis. The DLQI-R
scoring improved the discriminatory power of the question-
naire by benefiting from the additional information in items
marked as ‘not relevant’. In the discussion, we provide an
overview of the potential clinical relevance of our findings,
including the magnitude of the problem with NRRs, the bene-
fits, drawbacks and practical implications of applying the
DLQI-R scoring.
Recently, a number of concerns have been expressed about
NRRs on the DLQI.8–10,13 In three independent studies the fre-
quency of NRRs was increased among those with more severe
disease, suggesting that the DLQI may underestimate disease
severity in patients with psoriasis who responded NRR to one
or more items.8–10 To investigate the magnitude of the prob-
lem all three studies reported the number of patients affected
by NRRs. In Germany, 48% out of 1243 patients, in the
U.S.A. 23% of 1724 patients and in Hungary 388% of 428
Fig 2. Average Shannon’s indices of the 10 items per DLQI score band in the pooled dataset. (a) The distribution of patients with NRRs (n = 261)
according to DLQI defined score bands was as follows: DLQI 0–1: n = 77 (295%); DLQI 2–5: n = 60 (230%); DLQI 6–10: n = 55 (211%);
DLQI 11–20: n = 65 (249%) and DLQI 21–30: n = 4 (15%). (b) The distribution of patients (n = 637) according to DLQI defined score bands
was as follows: DLQI 0–1: n = 241 (378%); DLQI 2–5: n = 146 (229%); DLQI 6–10: n = 99 (155%); DLQI 11–20: n = 120 (188%) and DLQI
21–30: n = 31 (49%). H0max index values were 2 for the DLQI and the first two items of DLQI-R, and 232 for items 3–10 of DLQI-R in all
score bands. DLQI, Dermatology Life Quality Index; DLQI-R, DLQI-Relevant; NRR, ‘not relevant’ response.
© 2019 The Authors. British Journal of Dermatology
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patients included at least one NRR.8–10 In the present study,
the proportion of patients with NRRs varied between 366%
and 537%. These findings from a total of six patient popula-
tions in three different chronic skin conditions underscore the
clinical importance of the problem with NRRs.
There is increasing evidence about the potential benefits
of using the DLQI-R scoring. Firstly, as the DLQI-R is a
method of scoring the original DLQI, not a new or a
revised version of the DLQI, the integrity of the question-
naire remains intact.
Table 3 Absolute and relative informativity of Dermatology Life Quality Index (DLQI) and DLQI-Relevant (DLQI-R) total scores
Condition, scoring
Patients with NRRs All patients
Number of scores used (%) H0a J0 Number of scores used (%) H0a J0
Morphea
DLQI 14 (45) 332 067 17 (55) 342 069
DLQI-Rb 16 (52) 355 072 19 (61) 352 071
Pemphigus
DLQI 18 (58) 364 073 22 (71) 352 071
DLQI-Rb 25 (81) 406 082 26 (84) 372 075
Psoriasis
DLQI 23 (74) 415 084 29 (94) 407 082
DLQI-Rb 27 (87) 436 088 31 (100) 415 084
Pooled dataset
DLQI 24 (77) 407 082 29 (94) 397 080
DLQI-Rb 31 (100) 438 088 31 (100) 409 082
NRR, ‘not relevant’ response; H0, Shannon’s index; J0, Shannon’s evenness index. aH0max = 495 for both the DLQI and DLQI-R; bDLQI-R
scores are rounded to the nearest integers to have an identical number of possible scores as the DLQI (i.e. 31).
Fig 3. Scoring chart for DLQI-R. DLQI, Dermatology Life Quality Index; DLQI-R, DLQI-Relevant.
© 2019 The Authors. British Journal of Dermatology
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Secondly, DLQI-R showed improved measurement proper-
ties, including validity,11,12 responsiveness14 and discrimina-
tory power in comparison with the DLQI. Its convergent
validity with widely acknowledged generic HRQoL measures,
the EuroQol 5-Dimension 3-Level (EQ-5D-3L) and EuroQol
visual analogue scale (EQ VAS), was found to be statistically
significantly better.11,12 A 12-week clinical trial demonstrated
that in patients with psoriasis who marked one or more NRRs,
the DLQI-R was more responsive compared with the DLQI.14
The favourable measurement properties of the DLQI-R may be
equally useful in clinical trials as in daily clinical practice. In
particular, applying the DLQI-R may be considered in the fol-
lowing clinical situations: diagnosing moderate-to-severe dis-
ease, deciding on the need for admission to a hospital ward,
initiating systemic treatments and monitoring the response to
treatment.4,28–30
Thirdly, DLQI-R may help to improve the access to systemic
treatments for patients with psoriasis who cannot comply with
the DLQI > 10 criterion in treatment guidelines because cer-
tain items of the questionnaire are not relevant to them.11 In a
previous study, switching to the DLQI-R allowed 33 percent-
age points more patients with moderate-to-severe psoriasis to
achieve the ‘Psoriasis Area and Severity Index > 10 and
DLQI > 10’ threshold set out by treatment guidelines.11 Other
authors, however, argued that instead of changing the scoring
of DLQI, rather the criteria of the ‘Rule of Tens’ need to be
interpreted in a less absolute way.31
With regard to the limitations of the DLQI-R, calculating a
DLQI-R score may prolong the consultation and seem burden-
some in a time-pressured clinical environment. On the other
hand, the formula of the DLQI-R cannot be considered very
complicated, and the estimated calculation time is less than a
minute. From a practical perspective, developing scoring aids
is a reasonable solution to facilitating the pen-and-paper
administration. The Oswestry Disability Index (ODI)32 – the
most commonly applied instrument to measure disability
related to low back pain – has a very similar scoring system to
the DLQI-R. Building on a previously published and success-
fully applied scoring aid for the ODI,33 we developed a possi-
ble scoring chart for DLQI-R (Fig. 3). In the long run, a more
effective solution would be migrating to an electronic format
with a built-in option for the DLQI-R scoring formula. An
electronic version of the DLQI has been available since
2017.34,35 The paperless era of medicine is getting closer and
closer bringing forth the daily use of patient-reported out-
come measures in an electronic format. In such an environ-
ment, the seemingly complicated formula of the DLQI-R may
no longer will be an issue.
Our study has a few limitations. Shannon’s indices are
specific for these three patient populations under study and
may not be generalizable to other patient populations. The
sample sizes of the two rare diseases, namely pemphigus and
morphea populations are relatively small; however, both of
our datasets are among the largest HRQoL studies in these
diagnoses in Europe.17,18 The limited sample size of the study
did not allow us to compare directly the item-level
informativity for each DLQI total score category between zero
and 30 points. Furthermore, the DLQI and DLQI-R scores are
identical in patients with no NRRs not allowing any compar-
isons between the two scoring approaches. As a result of this
inherent property of the DLQI-R scoring, the difference
between the DLQI and DLQI-R will always be smaller at a
population level compared with what can be observed in the
subgroup of patients who marked NRRs.
The following possible future research areas are identified.
Firstly, there is currently little experience with using the
DLQI-R. We encourage physicians to try out the DLQI-R scor-
ing chart and encourage researchers with access to existing
DLQI data to experiment with the DLQI-R scoring and publish
the results. Secondly, although the better measurement proper-
ties of the DLQI-R in psoriasis seem to be established,11,12,14
further studies testing the performance of DLQI-R in other
dermatological conditions are needed. Thirdly, the perfor-
mance and the benefits of the DLQI and DLQI-R in the routine
clinical environment are yet to be investigated. Fourthly, find-
ing ways to integrate the DLQI-R scoring formula in the elec-
tronic version of the DLQI would be beneficial. Fifthly,
exploring how patients interpret the NRRs and whether they
are able to differentiate between the terms ‘not relevant’ and
‘not at all’ deserve further study.36,37 Finally, the established
banding system27 and the ‘Rule of Tens’38 are among the
greatest advantages of the DLQI that allow the clinical inter-
pretation of scores. Future studies are required to test whether
the Hongbo’s banding system can be applied to DLQI-R and,
if so, under what rules.27 It also needs to be defined when the
change in DLQI-R becomes ‘significant’ to a patient (i.e. mini-
mal clinically important difference).31 This would be an essen-
tial step to get the DLQI-R scoring accepted by professional
societies and treatment guidelines.
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